Trial Profile
A Phase I/II Study of Lenalidomide [Revlimid] in Combination with Gemcitabine in Patients with Untreated Advanced Carcinoma of the Pancreas
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2014
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 29 Oct 2005 New trial record.